[go: up one dir, main page]

MX2020009394A - Anticuerpos anti-cd73 y métodos de uso de los mismos. - Google Patents

Anticuerpos anti-cd73 y métodos de uso de los mismos.

Info

Publication number
MX2020009394A
MX2020009394A MX2020009394A MX2020009394A MX2020009394A MX 2020009394 A MX2020009394 A MX 2020009394A MX 2020009394 A MX2020009394 A MX 2020009394A MX 2020009394 A MX2020009394 A MX 2020009394A MX 2020009394 A MX2020009394 A MX 2020009394A
Authority
MX
Mexico
Prior art keywords
antibodies
methods
present disclosure
binding moiety
antagonize
Prior art date
Application number
MX2020009394A
Other languages
English (en)
Inventor
Olga Ignatovich
Nicholas Stuart Wilson
Jeremy Dale Waight
Shawn Michael Jennings
Benjamin Maxime Morin
Emmanuel Cyrille Pascal Briend
Oliver Schon
Spencer Campbell
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of MX2020009394A publication Critical patent/MX2020009394A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación proporciona anticuerpos que se unen a CD73 (por ejemplo, CD73 humana) y antagoniza la función de CD73. Asimismo, se proporcionan anticuerpos anti-CD73 que comprenden además una porción de unión a TGFß o una porción de unión a VEGF. La presente divulgación proporciona adicionalmente composiciones farmacéuticas que comprenden estos anticuerpos, ácidos nucleicos que codifican estos anticuerpos, vectores de expresión y células hospederas para producir estos anticuerpos y métodos para tratar a un sujeto usando estos anticuerpos.
MX2020009394A 2018-03-09 2019-03-08 Anticuerpos anti-cd73 y métodos de uso de los mismos. MX2020009394A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862640850P 2018-03-09 2018-03-09
PCT/US2019/021313 WO2019173692A2 (en) 2018-03-09 2019-03-08 Anti-cd73 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2020009394A true MX2020009394A (es) 2021-01-15

Family

ID=65904555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020009394A MX2020009394A (es) 2018-03-09 2019-03-08 Anticuerpos anti-cd73 y métodos de uso de los mismos.

Country Status (19)

Country Link
US (2) US11692042B2 (es)
EP (1) EP3762421A2 (es)
JP (2) JP7319992B2 (es)
KR (1) KR20200130403A (es)
CN (2) CN112074535B (es)
AR (1) AR114275A1 (es)
AU (2) AU2019231791B2 (es)
BR (1) BR112020017382A2 (es)
CA (1) CA3093468A1 (es)
CL (1) CL2020002314A1 (es)
CR (1) CR20200392A (es)
EA (1) EA202091710A1 (es)
IL (1) IL276731A (es)
MX (1) MX2020009394A (es)
PE (1) PE20210628A1 (es)
PH (1) PH12020551317A1 (es)
SG (1) SG11202007927WA (es)
TW (1) TWI823906B (es)
WO (1) WO2019173692A2 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2016104657A1 (ja) * 2014-12-26 2017-10-12 株式会社セラバイオファーマ 癌治療剤
NZ753714A (en) 2017-01-24 2023-03-31 I Mab Biopharma Co Ltd Anti-cd73 antibodies and uses thereof
KR20200139153A (ko) 2018-02-27 2020-12-11 인사이트 코포레이션 A2a / a2b 억제제로서의 이미다조피리미딘 및 트리아졸로피리미딘
CN112074535B (zh) * 2018-03-09 2024-10-11 艾吉纳斯公司 抗cd73抗体及其使用方法
MA52940A (fr) 2018-05-18 2021-04-28 Incyte Corp Dérivés de pyrimidine fusionnés utilisés en tant qu'inhibiteurs de a2a/a2b
JP7490631B2 (ja) 2018-07-05 2024-05-27 インサイト・コーポレイション Ａ２ａ／ａ２ｂ阻害剤としての縮合ピラジン誘導体
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
PH12021553256A1 (en) 2019-06-25 2022-08-08 Gilead Sciences Inc Flt3l-fc fusion proteins and methods of use
PH12022550509A1 (en) 2019-09-06 2023-03-20 Servier Lab Anti-cd73 antibodies
PL4045083T3 (pl) 2019-10-18 2024-05-13 Forty Seven, Inc. Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
KR20220100929A (ko) * 2019-11-15 2022-07-18 젠자임 코포레이션 이중파라토프성 cd73 항체
SI4081305T1 (sl) 2019-12-24 2025-03-31 Carna Biosciences, Inc. Spojine, ki modulirajo diacilglicerol kinazo
TWI877278B (zh) * 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
IL294437A (en) 2020-01-03 2022-09-01 Incyte Corp Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
US12018089B2 (en) * 2020-01-03 2024-06-25 Incyte Corporation Anti-CD73 antibodies and uses thereof
CN115087488A (zh) 2020-02-14 2022-09-20 震动疗法股份有限公司 与ccr8结合的抗体和融合蛋白及其用途
US20230133775A1 (en) * 2020-04-01 2023-05-04 The Regents Of The University Of California Immunotheranostic agent targeting mesenchymal stem cell-derived cancer cells and mesenchymal stem cell associated disease
WO2021247188A1 (en) 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
AU2021297856A1 (en) * 2020-06-22 2023-02-02 Innovent Biologics (Suzhou) Co., Ltd. Anti-CD73 antibody and use thereof
CN113817770B (zh) * 2020-08-12 2024-04-05 百奥赛图(北京)医药科技股份有限公司 Cd73基因人源化的非人动物的构建方法及应用
JP2023537115A (ja) * 2020-08-13 2023-08-30 イナート・ファルマ・ソシエテ・アノニム 抗ｃｄ７３抗体を使用する癌処置方法
WO2022064399A1 (en) * 2020-09-23 2022-03-31 Medimmune, Llc Treatment methods using anti-cd73 and anti-pd-l1 antibodies and chemotherapy
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
US20230416394A1 (en) * 2020-11-27 2023-12-28 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfbeta
WO2022147092A1 (en) 2020-12-29 2022-07-07 Incyte Corporation Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
JP7691720B2 (ja) * 2021-02-24 2025-06-12 蘇州近岸蛋白質科技股▲ふん▼有限公司 抗ヒトｃｄ７３抗体およびその適用
TW202302145A (zh) 2021-04-14 2023-01-16 美商基利科學股份有限公司 ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症
JP2024517181A (ja) 2021-04-28 2024-04-19 ウエヌイグレックオ・ファーマ 組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
WO2022245671A1 (en) 2021-05-18 2022-11-24 Gilead Sciences, Inc. Methods of using flt3l-fc fusion proteins
WO2022256620A1 (en) * 2021-06-03 2022-12-08 The Broad Institute, Inc. Novel targets for enhancing anti-tumor immunity
CN117651554A (zh) * 2021-06-11 2024-03-05 吉利德科学公司 Mcl-1抑制剂与抗癌剂的组合
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
CN117396478A (zh) 2021-06-23 2024-01-12 吉利德科学公司 二酰基甘油激酶调节化合物
KR20240023629A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
KR20240023628A (ko) 2021-06-23 2024-02-22 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
US11932634B2 (en) 2021-06-23 2024-03-19 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
EP4330289A1 (en) * 2021-07-05 2024-03-06 Trion Research GmbH Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
EP4116330A1 (en) * 2021-07-05 2023-01-11 Trion Research GmbH Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer
US20230183216A1 (en) 2021-10-28 2023-06-15 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CR20240173A (es) 2021-10-29 2024-06-20 Gilead Sciences Inc Compuestos de cd73
EP4452414A2 (en) 2021-12-22 2024-10-30 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
WO2023122615A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
TW202340168A (zh) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Ｐａｒｐ７抑制劑
CN119096300A (zh) * 2022-02-09 2024-12-06 艾伯赛公司 利用生成式人工智能解锁从头抗体设计
WO2023164625A2 (en) * 2022-02-25 2023-08-31 Georgia Tech Research Corporation Modified plant virus system for delivery of nucleic acids into mammalian cells
HUE069263T2 (hu) 2022-03-17 2025-02-28 Gilead Sciences Inc Ikarosz cink-ujj család degradálói és azok alkalmazása
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TWI876305B (zh) 2022-04-05 2025-03-11 美商基利科學股份有限公司 用於治療結腸直腸癌之組合療法
EP4507736A1 (en) 2022-04-13 2025-02-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
IL316058A (en) 2022-04-21 2024-11-01 Gilead Sciences Inc Compounds modulate KRAS G12D
CN117257934A (zh) * 2022-06-22 2023-12-22 中山康方生物医药有限公司 药物组合物及其用途
IL317958A (en) 2022-07-01 2025-02-01 Gilead Sciences Inc CD73 compounds
WO2024010842A1 (en) * 2022-07-07 2024-01-11 The Board Of Trustees Of The Leland Stanford Junior University Targeting cells with a combination of cxcr2 inhibition and cd47 blockade
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024064668A1 (en) 2022-09-21 2024-03-28 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY
WO2024124164A2 (en) * 2022-12-09 2024-06-13 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of immunostimulatory cytokines to chimeric antigen receptor immune cells
CN120225509A (zh) 2022-12-22 2025-06-27 吉利德科学公司 Prmt5抑制剂及其用途
CN118684781A (zh) * 2023-03-21 2024-09-24 深圳赫兹生命科学技术有限公司 GnRH-VLP重组去势疫苗及其制备方法
WO2024215754A1 (en) 2023-04-11 2024-10-17 Gilead Sciences, Inc. Kras modulating compounds
CN118812710A (zh) * 2023-04-17 2024-10-22 上海鑫湾生物科技有限公司 特异性结合cd73的抗体及其制备方法和应用
WO2024220917A1 (en) 2023-04-21 2024-10-24 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2024232976A1 (en) * 2023-05-07 2024-11-14 Bioatla, Inc. Protein therapeutics for treatment of senescent cells
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025006720A1 (en) 2023-06-30 2025-01-02 Gilead Sciences, Inc. Kras modulating compounds
US20250042971A1 (en) * 2023-07-25 2025-02-06 Immunitybio, Inc. LAIR-2 Compositions and Methods
WO2025024811A1 (en) 2023-07-26 2025-01-30 Gilead Sciences, Inc. Parp7 inhibitors
US20250066328A1 (en) 2023-07-26 2025-02-27 Gilead Sciences, Inc. Parp7 inhibitors
US20250101042A1 (en) 2023-09-08 2025-03-27 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2025054530A1 (en) 2023-09-08 2025-03-13 Gilead Sciences, Inc. Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds
WO2025076440A1 (en) * 2023-10-04 2025-04-10 Agenus Inc. TGFβRII EXTRACELLULAR REGION VARIANTS AND USES THEREOF
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025096589A1 (en) 2023-11-03 2025-05-08 Gilead Sciences, Inc. Prmt5 inhibitors and uses thereof
WO2025113643A1 (en) 2023-12-01 2025-06-05 Gilead Sciences Inc. Anti-fap-light fusion protein and use thereof
US20250230168A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN118420709B (zh) * 2024-04-29 2025-02-14 南京鼓楼医院 靶向cd73的肿瘤抗原肽、疫苗及其制备方法和应用

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2136016B (en) 1983-03-07 1987-01-07 Sheena Margaret Johnson Monoclonal factor having 5'-nucleotidase inhibitory activity
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
ES2174868T3 (es) 1992-10-29 2002-11-16 Celtrix Pharma Fragmento del receptor de fijacion a tgf-beta tipoii como agente terapeutico.
US5470952A (en) 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
PT1695985E (pt) 1997-04-07 2011-06-06 Genentech Inc Métodos para formar anticorpos humanizados por mutagénese aleatória
DE69836729T2 (de) 1997-04-07 2007-12-13 Genentech, Inc., South San Francisco Anti-vefg antibodies
BR9808934A (pt) 1997-04-18 2000-08-01 Biogen Inc Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
US6472179B2 (en) 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
NZ514914A (en) 1999-05-07 2004-09-24 Genentech Inc Treatment of autoimmune diseases with antagonists which bind to B cell surface markers
US7306799B2 (en) 1999-06-08 2007-12-11 Regeneron Pharmaceuticals, Inc. Use of VEGF inhibitors for treatment of eye disorders
KR20020093029A (ko) 2000-04-11 2002-12-12 제넨테크, 인크. 다가 항체 및 그의 용도
CN1437478A (zh) 2000-04-25 2003-08-20 Idec药物公司 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗
WO2002072605A2 (en) 2001-03-07 2002-09-19 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
JP2006522811A (ja) 2003-04-09 2006-10-05 ジェネンテック・インコーポレーテッド ＴＮＦαインヒビターに対して不十分な反応を示す患者の自己免疫疾患治療法
US7786261B2 (en) 2004-09-02 2010-08-31 National Research Council Of Canada Coiled-coil fusion proteins comprising cell receptor domains
US7795389B2 (en) 2004-09-28 2010-09-14 The Board Of Regents Of The University Of Texas System Antagonizing TGF-beta activity with various ectodomains TGF-beta receptors used in combination or as fusion proteins
AR052056A1 (es) 2004-12-17 2007-02-28 Genentech Inc Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo
WO2006088650A2 (en) 2005-02-02 2006-08-24 Regeneron Pharmaceuticals, Inc. Method of treating eye injury with local administration of a vegf inhibitor
EP1850873B1 (en) 2005-02-08 2018-11-28 Genzyme Corporation Antibodies to tgfbeta
MX2007014463A (es) 2005-05-18 2008-04-07 Biogen Idec Inc Metodos para tratar condiciones fibroticas.
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA3149553C (en) 2006-06-12 2023-11-21 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
WO2008007648A1 (fr) 2006-07-10 2008-01-17 Institute For Antibodies Co., Ltd. Procédé de classification d'antigène, procédé d'identification d'antigène, procédé d'obtention d' un ensemble d'antigènes ou d'anticorps, procédés de construction d'un panel d'anticorps, anticorps et ens
US8318135B2 (en) 2007-03-19 2012-11-27 National Research Council Of Canada Antagonist of ligands and uses thereof
EP2171062A1 (en) 2007-06-15 2010-04-07 Genzyme Corporation Fusion proteins containing two tgf-beta binding domains of tgf-beta type ii receptor
CA2729810A1 (en) 2008-07-02 2010-01-07 Emergent Product Development Seattle, Llc Tgf-.beta. antagonist multi-target binding proteins
EP2542590B2 (en) 2010-03-05 2020-04-01 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
US20130109645A1 (en) 2010-03-31 2013-05-02 The united States of America,as represented by Secretary,Dept.,of Health and Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
USRE49280E1 (en) 2012-03-28 2022-11-08 Board Of Regents, The University Of Texas System TGFbeta type II-type III receptor fusions
CN110041431A (zh) * 2012-04-30 2019-07-23 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
WO2014164427A1 (en) 2013-03-12 2014-10-09 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
US9090697B2 (en) 2013-03-15 2015-07-28 Bayer Healthcare Llc Methods for treating bleeding disorders
WO2014153424A1 (en) 2013-03-19 2014-09-25 La Jolla Institute For Allergy And Immunology Reducing diabetes in patients receiving hmg-coa reductase inhibitors (statins)
WO2014172584A1 (en) 2013-04-17 2014-10-23 Baylor College Of Medicine IMMUNOSUPPRESSIVE TGF-β SIGNAL CONVERTER
WO2015006500A2 (en) 2013-07-09 2015-01-15 President And Fellows Of Harvard College Endothelial cell genes and uses thereof
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
CA2931309C (en) 2013-11-21 2022-06-21 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
AR098827A1 (es) 2013-12-19 2016-06-15 Consejo Nac De Investig Científicas Y Técnicas (Conicet) ISOFORMA DEL RECEPTOR II DE TGF-b, POLINUCLEÓTIDOS QUE LA CODIFICAN VECTORES, CÉLULAS TRANSFORMADAS, PÉPTIDOS Y DE FUSIÓN, MÉTODO Y USOS
PE20210168A1 (es) 2014-02-10 2021-01-28 Merck Patent Gmbh INHIBICION DIRIGIDA DEL FACTOR DE CRECIMIENTO TRANSFORMADOR ß (TGFß)
DK3204417T3 (da) 2014-10-10 2020-10-12 Innate Pharma Cd73-blokering
US20180030144A1 (en) 2014-10-10 2018-02-01 Innate Pharma Cd73 blockade
WO2016131950A1 (en) * 2015-02-20 2016-08-25 Innate Pharma Cd73 blockade
EP3901176A1 (en) 2014-11-10 2021-10-27 MedImmune Limited Binding molecules specific for cd73 and uses thereof
HK1246304A1 (zh) 2014-11-11 2018-09-07 Medimmune Limited 包含抗cd73抗體和a2a受體抑制劑的治療組合及其用途
EA202090956A3 (ru) * 2014-11-21 2020-12-30 Бристол-Майерс Сквибб Компани Антитела к cd73 и их применения
CN113683709A (zh) 2015-04-06 2021-11-23 阿塞勒隆制药公司 单臂i型和ii型受体融合蛋白和其用途
EP3316902A1 (en) 2015-07-29 2018-05-09 Novartis AG Combination therapies comprising antibody molecules to tim-3
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
CA2996996A1 (en) 2015-08-31 2017-03-09 National Research Council Of Canada Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof
US11130817B2 (en) 2015-10-12 2021-09-28 Innate Pharma CD73 blocking agents
AU2016366548C1 (en) 2015-12-09 2024-07-25 Bioatla, Llc Humanized anti-CD73 antibodies
WO2017118613A1 (en) * 2016-01-08 2017-07-13 Syddansk Universitet Bispecific antibodies targeting human cd73
WO2017134592A1 (en) 2016-02-03 2017-08-10 Biocon Limited Anti-cd20/immunomodulatory fusion proteins and methods for making same
AU2017228474C1 (en) 2016-03-04 2024-03-28 Abmuno Therapeutics Llc Antibodies to TIGIT
AU2017228470A1 (en) 2016-03-04 2018-08-30 Bristol-Myers Squibb Company Combination therapy with anti-CD73 antibodies
US20200232974A1 (en) 2016-03-30 2020-07-23 Centre Léon-Bérard Lymphocytes expressing cd73 in cancerous patient dictates therapy
CN109414500B (zh) 2016-06-13 2022-02-25 奥美药业有限公司 治疗和诊断用pd-l1特异性单克隆抗体
US10793636B2 (en) 2016-07-11 2020-10-06 Corvus Pharmaceuticals, Inc. Anti-CD73 antibodies
EP3556773A4 (en) 2016-12-13 2020-08-19 Astellas Pharma Inc. HUMAN ANTI-CD73 ANTIBODY
NZ753714A (en) 2017-01-24 2023-03-31 I Mab Biopharma Co Ltd Anti-cd73 antibodies and uses thereof
WO2018215535A1 (en) 2017-05-23 2018-11-29 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
CN112074535B (zh) * 2018-03-09 2024-10-11 艾吉纳斯公司 抗cd73抗体及其使用方法

Also Published As

Publication number Publication date
AU2022259823A1 (en) 2022-12-01
EA202091710A1 (ru) 2021-02-16
CR20200392A (es) 2020-11-17
EP3762421A2 (en) 2021-01-13
CA3093468A1 (en) 2019-09-12
US20190352418A1 (en) 2019-11-21
JP7319992B2 (ja) 2023-08-02
KR20200130403A (ko) 2020-11-18
US20230416397A1 (en) 2023-12-28
AU2019231791A1 (en) 2020-09-03
AR114275A1 (es) 2020-08-12
TWI823906B (zh) 2023-12-01
BR112020017382A2 (pt) 2021-01-26
TW201945391A (zh) 2019-12-01
PH12020551317A1 (en) 2021-09-01
SG11202007927WA (en) 2020-09-29
CN112074535B (zh) 2024-10-11
CL2020002314A1 (es) 2021-03-05
CN112074535A (zh) 2020-12-11
CN119431579A (zh) 2025-02-14
JP2021515559A (ja) 2021-06-24
PE20210628A1 (es) 2021-03-23
US11692042B2 (en) 2023-07-04
JP2023129543A (ja) 2023-09-14
WO2019173692A3 (en) 2019-11-14
WO2019173692A2 (en) 2019-09-12
IL276731A (en) 2020-09-30
AU2019231791B2 (en) 2022-08-11

Similar Documents

Publication Publication Date Title
MX2020009394A (es) Anticuerpos anti-cd73 y métodos de uso de los mismos.
MX2024009690A (es) Anticuerpos anti-cd137 y metodos de uso de los mismos.
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CL2020002231A1 (es) Anticuerpos anti-pd1 y sus métodos de uso (divisional solicitud 201800490)
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
AR111288A1 (es) Anticuerpos anti-phf-tau y sus usos
ECSP19011185A (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a CD3 y CD123
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
CO2020000214A2 (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos
CO2018011364A2 (es) Anticuerpos anti-il-33, composiciones, métodos y usos de los mismos
MX2017003268A (es) Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
MX2021013161A (es) Polipeptidos que contienen dominios de union de novo y usos de los mismos.
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
ECSP22014455A (es) Anticuerpos anti-cd96 y sus métodos de uso
UY35964A (es) Anticuerpos humanos para pd?1
CL2022000096A1 (es) Anticuerpos anti-tigit y aplicación de los mismos
CL2017002705A1 (es) Anticuerpos que se dirigen a la proteína morfogénica ósea 9 (bmp9) y a los métodos a los que se refieren
CL2020001137A1 (es) Anticuerpos anti-apoc3 y métodos de uso de estos.
BR112016017764A2 (pt) anticorpo antidengue de amplo espectro
BR112022012731A2 (pt) Anticorpo anti-ox40 e uso do mesmo
AR125753A1 (es) Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos
AR112758A1 (es) Anticuerpos agonistas que unen cd137 humano, y usos de los mismos
AR109825A1 (es) ANTICUERPOS DE INTERFERÓN b Y USOS DE LOS MISMOS